Thursday, May 30, 2013

Amgen and Astellas enter into a strategic Alliance for Japanese Market

There are two parts of the strategic alliance
  1. The first element of the alliance is a long-term collaboration between the two companies that will focus on the co-development and co-commercialization in Japan of five Amgen pipeline medicines. (Table 1)
  2. The second element of the alliance is the establishment of a Tokyo-based joint venture company through which the companies will work together to enable Amgen to rapidly build on-the-ground capabilities in Japan. The joint venture will operate under the name Amgen Astellas BioPharma KK and will be led by Eiichi Takahashi, who will serve as general manager. Additional management roles will be appointed by Amgen and Astellas. The joint venture will be staffed by seconded employees from Astellas, transferred employees from Amgen and newly hired employees. It is expected that the joint venture will start operations on Oct. 1, 2013, and will become a wholly owned Amgen affiliate as soon as 2020 with the long-term collaboration continuing.  Through this strategic alliance with Astellas, Amgen intends to leverage Astellas extensive knowledge of the local market to accelerate development and commercialization of Amgen medicines for patients in Japan.

Table 1
Molecule


Lead Indication

Mode of Action
Development Stage

Global


Japan

AMG 145

Hyperlipidemia  Anti-PCSK-9 mAb Phase 3 Phase 2

Romosozumab (AMG 785)

Osteoporosis Anti-Sclerostin mAb Phase 3 Phase 2/3

Rilotumumab
(AMG 102)

Gastric Cancer Anti-HGF mAb Phase 3 Phase 1

AMG 337

Gastric Cancer MET inhibitor Phase 1

Blinatumomab
(AMG 103)


Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s Lymphoma (NHL)

Anti-CD19 BiTE® Phase 2